Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

December 8, 2023

USFDA accepts NextPoint Therapeutics’s IND for NPX887

NextPoint Therapeutics has announced that its investigational new drug (IND) application has been accepted by the US Food & Drug Administration (FDA) for NPX887.

USFDA accepts NextPoint Therapeutics’s IND for NPX887